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Abstract
Background: Earlier studies have shown that the absolute number of neutrophil granulocytes (NGs) may increase
during attack of hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE). Whether NGs undergo
activation during attack has not yet been investigated. However, as neutrophil elastase (NE) can cleave and
inactivate C1-INH which may contribute to the dysregulation of the kallikrein-kinin system and hence, to edema
formation. Our aim was to investigate the possible activation of NGs during attacks.
Methods: We studied blood samples obtained from 26 patients with C1-INH-HAE during symptom-free periods and
during attacks, along with samples from 26 healthy volunteers. NG count (NGC), NE, myeloperoxidase (MPO), pentraxin
3 (PTX3), CRP, C5a, factor H, IL-8, and TNF-α levels were measured.
Results: NGC was higher during attacks than during symptom-free periods (p = 0.0132), and the same was observed
for NE (p = 0.0026), MPO (p = 0.0008), and PTX3 levels (p = 0.0409). There was a strong positive correlation between NE
and MPO levels during attacks (p < 0.0001, R = 0.709). Furthermore, IL-8 (p = 0.0061) and TNF-α (p = 0.0186) levels were
also elevated during attacks, compared with symptom-free periods. By contrast, C5a and factor H levels were similar in
samples obtained during attacks or in symptom-free periods.
Conclusion: Increased NGC was associated with elevated NE and MPO levels – this suggests neutrophil activation
during attacks. The strong positive correlation between NE and MPO levels, together with the elevated PTX3
concentration, may indicate the expression of neutrophil extracellular traps. All these processes may contribute
to the activation of kallikrein-kinin system, which leads to the onset of an edematous episode.
Keywords: Hereditary angioedema, C1-inhibitor deficiency, Edematous attack, Neutrophil granulocytes,
Neutrophil activation, Neutrophil elastase, Myeloperoxidase, IL-8, TNF-α
Background
Hereditary angioedema due to C1-inhibitor deficiency
(C1-INH-HAE) is a rare, autosomal dominant dis-
order. It is caused by the reduced antigenic level and/
or functional activity of the C1-inhibitor (C1-INH),
resulting from a mutation in the gene encoding C1-INH
(SERPING1) [1].
The serine protease inhibitor C1-INH is the primary
regulator of the classical and lectin complement
pathways—and also of the kallikrein-kinin, coagulation
and fibrinolytic systems [2]. In the deficiency of C1-
INH, the kallikrein-kinin system undergoes activation
and this result in the cleavage of bradykinin from high-
molecular-weight kininogen (HK)—a process catalyzed
by kallikrein. Bradykinin increases vascular permeability
and thereby induces the extravasation of plasma into
the tissues, leading to edema-formation [3].
C1-INH-HAE is characterized by recurring episodes of
subcutaneous and/or submucosal edema [4]. Acute
edema formation in the upper airways may even cause
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asphyxia from airway obstruction [5]. As the determi-
nants of the immediate cause, the time of onset, or
the location of edema formation remain unknown,
the occurrence of these episodes cannot be predicted
in advance. Although much progress has been made
during recent years in exploring the pathophysiology
of the disease, research has largely focused on the
role of the different plasma enzyme systems [3, 6].
Previously, a number of case studies reported the
elevation of white blood cell (WBC) count and neu-
trophil granulocyte counts (NGC) during edematous
attacks [7–10]. Some authors attributed this to hemocon-
centration from the extravasation of plasma during the
edematous episode [7, 8]. In 2010, our team confirmed
these reports in a study conducted on 18 HAE patients:
we found increased WBC count and NGC during
edematous episodes. Further, we showed that the
increase of NGC during the attack was greater than
could be explained by hemoconcentration [11].
Notwithstanding these findings, the possible activation
of NGs in HAE attacks has not yet been investigated.
This is all the more strange, since NGs are known to
have the potential to exert multiple influences on the
kallikrein-kinin system. Neutrophil elastase (NE) –re-
leased from activated NGs- can cleave and inactivate
C1-INH [12]. This may contribute to the dysregulation
of plasma enzyme systems and hence, to edema forma-
tion, as C1-inhibitor is the most potent regulator of the
kallikrein-kinin system, by controlling the activity of kal-
likrein and of activated factor XII [2]. The activation of
NGs may lead to the formation of neutrophil extracellu-
lar traps (NETs), which are filamentous structures of
DNA and histones containing granular enzymes [NE
and myeloperoxidase (MPO), primarily] along with anti-
microbial peptides [defensins, and pentraxin 3 (PTX3)]
[13, 14]. NETs can provide a negatively charged surface
suitable for the activation of the kallikrein-kinin and of
the complement systems [15, 16]. On the other hand,
the kallikrein-kinin system can be activated also on the
surface of neutrophils [17] (Fig. 1).
A variety of factors related to the activation of NGs
have been identified [18–20], and all these might have
their role in the pathomechanism of edema formation.
The objectives of our study were as follows:
1. To confirm the previously described increase of
NGC in a larger patient population, by analyzing
peripheral blood samples obtained from the same
C1-INH-HAE patients during symptomatic and
symptom-free periods.
2. To investigate the possible activation of NGs during
edematous episodes, by determining the levels of the
Fig. 1 Activation of neutrophil granulocytes and the kallikrein-kinin system. During neutrophil activation triggered by different substances,
the released neutrophil elastase could cleave and inactivate C1-INH [12]. Besides, activated neutrophils can release neutrophil extracellular
traps, and both processes may contribute to bradykinin release [13, 15]. On the other hand, high molecular weight kininogen and factor
XII can attach directly to the surface of NGs. Prekallikrein, by contrast, binds to the cell membrane indirectly, through its docking protein,
high molecular weight kininogen, which could create the conditions for the release of kinins (bradykinin and kallidin) through the activation of the
cell-bound kallikrein-kinin system. This would be manifested by the factor XII-mediated activation of prekallikrein on one hand, and/or by the release of
neutrophil-borne, active tissue kallikrein on the other [17]. [Abbreviations: IL = interleukin, TNF-α = tumor necrosis factor-α, LPS = lipopolysacharide,
HK = high molecular weight kininogen, PK = prekallikrein, tKal = tissue kallikrein, LK = low molecular weight kininogen, C1-INH = C1-inhibitor,
FXII = factor XII, MPO =myeloperoxidase, PTX3 = pentraxin 3]
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enzymes NE and MPO (both released from primary
granules during activation), as well as of the protein
PTX3 (released from secondary granules) in
peripheral blood samples [20].
3. To measure the levels of interleukin-8 (IL-8) and
tumornecrosis factor-α (TNF-α) (the cytokines with
the greatest influence on neutrophil activation), of
C5a (a complement anaphylatoxin, which induces
neutrophil activation), and of factor H (involved
in the regulation of neutrophil activation), as well




The subjects were selected from the patient population
(n = 172) receiving follow-up care at the Hungarian An-
gioedema Center. We included 26 patients (20 females,
6 males, mean age: 35.8 years) who presented at the
Center for treatment for an acute edematous episode; 19
patients had type I, whereas 7 had type II C1-INH-HAE.
The diagnosis of C1-INH-HAE was established by
pedigree-analysis, as well as by the evaluation of the
clinical manifestations and the complement parameters
(C1-INH antigenic and functional levels, C1q, C4). Nine
patients were on continuous danazol treatment, whereas
the remaining 17 did not receive long-term prophylaxis.
Human plasma-derived C1-INH concentrate (Berinert®,
CSL Behring, Marburg, Germany) was reserved for the
acute treatment of edematous attacks. The “symptom-
free samples” were collected during the annual control
visits. None of the patients had any clinical manifest-
ation suggestive of an acute infection during the edema-
tous attack and during annual control visits.
Healthy controls
The control group consisted of 26 healthy adults (19
females and 7 males, mean age: 35.2 years). All had
been referred for routine medical examination. The
healthy controls did not have any known disease, and
did not receive medicinal products at the time of
blood sampling. C1-INH deficiency was excluded by
complement testing (measuring antigenic and func-
tional level of C1-INH, C4, and C1q).
The C1-INH-HAE patients and the controls were
not statistically different as regards age and gender
distribution.
Blood sampling
Peripheral blood samples were obtained from patients
with C1-INH-HAE both during symptom-free periods
and during attacks (before acute treatment) as well as
from healthy subjects. EDTA plasma and serum samples
were stored at −70 °C until processing.
The study protocol was approved by the institutional
review board of Semmelweis University of Budapest, and
informed consent was obtained from the participants in
accordance with the Declaration of Helsinki.
Measurement of the parameters related to neutrophil
activation and to the complement parameters of C1-INH-HAE
WBC count, NGC, Red blood cell (RBC) count and
hematocrit were determined in the samples using Advia
120 Hematology System automate (Siemens, Erlangen,
Germany). A stable complex of NE with alpha1-
proteinase-inhibitor, and MPO were measured in EDTA-
plasma by sandwich type ELISA (QIA96, Calbiochem,
Merck-Millipore, Darmstadt, Germany, and Immundiag-
nostik AG, Bensheim, Germany). For the measurement
of PTX3 level, we used a Duoset ELISA kit (R&D sys-
tems, Minneapolis, USA). Commercially available high-
sensitivity ELISA kits were used to measure the levels of
cytokines (IL-8, TNF-α—R&D system, Minneapolis,
USA and Thermofisher Scientific Inc, Waltham, USA),
and of the C5a anaphylatoxin (Quidel, San Diego, USA)
in EDTA plasma. All procedures were carried out ac-
cording to the manufacturer’s instructions. Serum levels
of CRP were determined using a chemistry analyzer
(Beckman Coulter Inc., California, USA).
The concentration of factor H was determined with an
in-house sandwich ELISA method. In brief, 96-well
ELISA plates (Nunc, Denmark) were coated with 1:1000
dilution of sheep anti-human factor H IgG fraction (The
Binding Site Inc., Birmingham, UK), and incubated over-
night at 4 °C. The next day, the plates were blocked for
1 hour using PBS with 0.5 % BSA and then, incubated
containing serum samples diluted 1000-fold. A mixture of
sera from healthy individuals (concentration = 557 μg/ml,
calibrated with recombinant factor H) was used as ref-
erence standard after a seven-step series of two-fold di-
lutions, starting from a dilution ratio of 1:250. The
samples and the standard were diluted with PBS-Tween
containing 0.5 % BSA. After an 1-hour incubation,
mouse monoclonal anti-human factor H (Quidel, San
Diego, USA) was dispensed to the plates in 1:2000 dilu-
tion. Following incubation for an additional hour, goat
anti-mouse IgG-HRP (Southerm Biotech, Birmingham,
Alabama, USA) was added in 1:8000 dilution. 1,2-phenyl-
enediamine dihydrochloride (OPD, DAKO Denmark A/S,
Glostrup, Denmark) was used as substrate; the color re-
action was stopped by the addition of 0.4 N sulphuric
acid and optical density was measured at 492 and
620 nm wave lengths.
Radial immunodiffusion was performed to measure
C4 level (polyclonal rabbit anti-human C4c Comple-
ment, DAKO Denmark A/S, Glostrup, Denmark), as
well as the concentration of antigenic C1-INH (goat
antisera to human C1-INH, Quidel, San Diego, CA, USA).
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Functional C1-INH level was determined with a commer-
cially available ELISA kit (Quidel, San Diego, CA, USA),
according to the manufacturer’s recommendations.
All analyzed parameters were determined in the same,
previously unthawed aliquot from each subject.
Statistical analysis
Statistical analysis was performed with Prism for Win-
dows 5.0 (Graph-Pad Software, San Diego, CA, USA)
statistical software. As many of the variables had non-
Gaussian distributions, we used non-parametric tests
throughout the analysis. Mann–Whitney’s U-test was
applied to compare two independent groups (C1-INH-
HAE-patients vs. healthy controls), whereas the Wilcoxon
test (a paired t-test) was chosen to compare “symptom-
free” and “during attack” values from the same patients.
Correlations were calculated with the Spearman’s rho test.
All the statistical analyses were two-tailed, and p < 0.05
was considered to represent a significant difference, or
correlation.
Results
Analysis of neutrophil granulocyte counts
Because the extravasation of fluid into the extracellular
space may result in hemoconcentration of variable ex-
tent, we adjusted “during attack” WBC and NGC values
with the latter before making comparisons among the
study groups. The magnitude of hemoconcentration was
estimated in individual patients by taking into account
the ratio of RBC counts determined during attacks and
during symptom-free periods. The observed WBC count
and NGC measured in during attack samples were di-
vided by the calculated ratio (RBC count during attack/
RBC count during symptom-free period) in each patient,
to eliminate the changes induced by hemoconcentration.
We made the comparative analysis with these “cor-
rected” values. Comparing symptom-free C1-INH-HAE
patients and controls, we found higher NGC in patients
than in controls (median: 4.87 vs. 3.69 Giga/l; p = 0.0107,
Mann-Whitney test). Subsequently, we confirmed this
observation in another population of 114 C1-INH-HAE
patients and 210 healthy subjects (p = 0.0002). Moreover,
we found that compared with symptom-free periods, this
difference increases further during edematous episodes
(median: 4.87 vs. 5.74 Giga/l; p = 0.0132, paired t-test) in
the same C1-INH-HAE patients. We observed similar
differences among the three study groups with respect
to WBC [symptom-free vs. healthy controls (median:
7.52 vs. 6.19 Giga/l; p = 0.0165) and symptom-free vs.
during attack (median: 7.52 vs. 8.73 Giga/l; p = 0.0254)]
(Fig. 2). When we made the corrections for hemocon-
centration with the above mentioned methods, using
hematocrit values of each patient, we observed the same
significant differences between symptom-free and during
attack samples of the patients (p = 0.0212 for NG and
p = 0.0321 for WBC) as it was found when we made
the corrections using RBC values.
To probe for neutrophil activation
In order to analyze neutrophil activation, we measured
the levels of NE and of MPO, as well as of PTX3. In
symptom-free patients, none of these differed from the
corresponding values of healthy controls. However, the
levels of all three markers were significantly higher in
samples obtained during edematous attacks. The differ-
ences were statistically significant, compared both with
symptom-free samples of the same patients (NE:
35.90 vs. 26.40 ng/ml; p = 0.0026, MPO: 129.0 vs.
89.40 ng/ml; p = 0.0008; and PTX3: 1.28 vs. 0.98 ng/ml;
p = 0.0409), and with samples from healthy controls (NE:
35.90 vs. 26.07 ng/ml; p = 0.0043, MPO: 129.0 vs.
80.14 ng/ml; p = 0.0024; and PTX3: 1.28 vs. 0.82 ng/ml;
p = 0.0157) (Fig. 3).
Fig. 2 NGC‡ (a) and WBC‡ count (b) in blood samples drawn during attacks and in symptom-free periods from patients with C1-INH-HAE, and
from healthy controls. Median and interquartile ranges are shown. (*p < 0.05, **p < 0.01, and ***p < 0.001; Wilcoxon signed-rank test and
Mann-Whitney U test). ‡Absolute cell counts were corrected for hemoconcentration occurring during attacks
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Analysis of cytokines, CRP and complement factors
IL-8 levels were comparable in samples obtained from
symptom-free patients and from healthy controls.
During edematous attacks, however, IL-8 levels were
higher than during symptom-free periods [median
(25–75 percentile) 2.43(1.95–5.46) vs. 1.69 (0.82–2.71)
pg/ml; p = 0.0061] in the same C1-INH-HAE patients.
The situation was similar for TNF-α levels (1.27
(0.83–1.97) vs. 0.81 (0.04–1.64) pg/ml; p = 0.0186),
with the distinction that these were significantly lower
in symptom-free patients than in healthy controls
(median: 0.81 (0.04–1.64) vs.1.78 (0.56–2.30) pg/ml;
p = 0.0296). As the latter was an unexpected finding,
we repeated TNF-α measurements in another set of
samples from different C1-INH-HAE patients (n = 31)
and healthy individuals (n = 57). This check confirmed the
result of the above comparison, and showed significant
differences between the TNF-α levels in samples from
symptomatic or symptom-free patients (p = 0.0159), as
well as in those from symptom-free patients or healthy
controls (p = 0.0015).
Serum CRP level was higher during the symptom-free
period, compared with that observed in the healthy sub-
jects (median: 2.20 (1.85–3.78) vs. 1.50 (0.85–2.17) mg/l;
p = 0.0031), and increased further significantly during
attacks (median: 2.20 (1.85–3.78) vs. 3.39 (1.96–4.98)
mg/l; p = 0.0321) in the same C1-INH-HAE patients.
There were no significant differences between the C5a
and factor H levels measured in samples from the pa-
tients and from the controls (C5a: 9.61 (6.51–13.87)
vs.10.45 (7.92–14.04) ng/ml; p = n.s. and factor H: 711
(527–878) vs. 596 (431–775) μg/ml p = n.s.). The
same was found in samples obtained during attacks
or in symptom-free periods (C5a: 10.51(8.57–15.63)
vs. 9.61(6.51–13.87) ng/ml p = n.s.; factor H: 625
(533–711) vs. 711 (527–878) μg/ml; p = n.s.).
Relationships among the parameters measured in
patients with C1-INH-HAE and in healthy controls
Substantial neutrophil activation does not occur in
healthy individuals and hence, a significant correlation
between NGC and the levels of activation markers can-
not be expected. The analysis of the mutual relationships
among all parameters measured in healthy controls re-
vealed only one negative correlation—that is, between
the levels of TNF-α and of C5a (R = −0.4464, p = 0.0373).
Further, we did not find a significant correlation among
the parameters measured in the samples from symptom-
free C1-INH-HAE patients.
Fig. 3 The levels of NE (a), MPO (b), and PTX3 (c) in blood samples drawn during attacks and in symptom-free periods from patients, compared
with healthy controls. Median and interquartile ranges are shown. (*p < 0.05, **p < 0.01, and ***p < 0.001; Wilcoxon signed-rank test and
Mann-Whitney U test)
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On the other hand, we found many relationships among
the indices determined in the blood samples drawn during
edematous episodes. There was a strong positive correl-
ation between NGC and NE level (R = 0.6512, p = 0.0008),
and a slightly positive correlation between NGC and
MPO level (R = 0.4241, p = 0.0492). An even closer re-
lationship was revealed between NE and MPO levels
(R = 0.7090, p < 0.0001). Moreover, we found a positive
correlation also between factor H and TNF-α levels
(R = 0.5061, p = 0.0083) (Fig. 4). Significant relation-
ships could not be found for CRP, IL-8 and C5a.
Further, we searched for possible relationships among
the measured markers of neutrophil activation and the
diagnostic parameters of C1-INH-HAE (antigenic and
functional C1-INH, as well as C4 levels). None of these
parameters exhibited a significant correlation –neither
in samples from symptom-free periods, nor in those
obtained during edematous episodes.
Discussion
In our current study, we confirmed that NGC indeed in-
creases during edematous episodes of C1-INH-HAE—even
if the effect of hemoconcentration is taken into account.
Our study showed for the first time that NGC is higher in
C1-INH-HAE patients during symptom-free period than
in healthy controls. Further studies are necessary to
elucidate the mechanism behind this elevation and its pos-
sible relationship with C1-INH deficiency. We found that
NGs undergo activation during edematous episodes. This
is evidenced by the elevated levels of NE, MPO, and PTX3
(all released from the granules of the NGs) relative to those
found in blood samples obtained during symptom-free pe-
riods from the same patients. Apparently, the activation of
NGs is indeed related to edema formation. In particular,
the elevated NGC found in symptom-free patients is not
accompanied by an enhanced release of granulocytic en-
zymes, when compared with the values measured in
healthy controls.
In addition to elevated NE and MPO levels, the occur-
rence of neutrophil activation during edematous epi-
sodes is suggested also by the positive correlation
between NGC and NE level. This can be observed only
in blood samples drawn during edematous attacks, but
not in those obtained during symptom-free periods from
the same patients, or from healthy individuals. The rela-
tionship between the levels of NE and of MPO exhibited
an even stronger correlation. These relationships and
the elevation of PTX3 level during the attacks might
suggest the expression of NETs.
TNF-α and IL-8 are possible activators of neutrophil
functions [21–23]. We found elevated levels of these fac-
tors in blood samples drawn during edematous attacks,
Fig. 4 Statistically significant correlations between neutrophil granulocyte count and neutrophil elastase level (a), neutrophil granulocyte count
and myeloperoxidase level (b), neutrophil elastase and myeloperoxidase levels (c) and factor H and TNF-α levels (d) measured in the samples
drawn during attacks. Spearman’s rank correlation coefficient was calculated
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compared with those from symptom-free periods. Re-
markably, TNF-α levels were lower in the samples of
symptom-free patients than in those from healthy con-
trols. Although we confirmed this finding by extending
the measurements to samples from additional patients
and controls, we cannot offer any ideas as to its signifi-
cance. Only limited data have been published on the role
of cytokines in C1-INH-HAE, and even these are avail-
able from a small number of cases. Most of these studies
did not compare samples obtained from the same pa-
tients during and between edematous attacks, and all
analyzed serum samples [24–26]. Serum is the least
suitable sample type for measuring cytokine levels.
According to comparative appraisals, EDTA plasma is
the most appropriate for this purpose, because it is
more stable than lithium-heparin, ammonium-heparin
or, serum samples [27, 28].
The elevated level of TNF-α and IL-8 seen during
edematous episodes might be related to neutrophil acti-
vation. On one hand, these cytokines could activate NGs
and on the other hand, the latter themselves can pro-
duce both cytokine [20].
We made the interesting observation that serum CRP
level was elevated in the symptom-free period, com-
pared with that observed in the healthy subjects, and it
increased further significantly during attacks in the
same C1-INH-HAE patients. The latter observation is
in agreement with previous findings [29]. Although
NGs are inflammatory cells, we could not detect any
significant correlation among NGC, TNF-alpha, and
CRP levels.
Complement is a first-line defense of innate immunity,
which aids the clearance of pathogens by opsonic, lytic,
inflammatory, and immunomodulatory activities [30].
The C5a complement anaphylatoxin is a strong chemo-
attractant for neutrophils and a mediator of neutrophil
adhesion [31, 32]. Factor H is a complement inhibitor,
and also controls cell activation and adhesion through
binding to the iC3b receptors present on the surface of
neutrophils [19]. We did not find any differences be-
tween C5a and factor H levels measured in samples
from symptomatic or symptom-free patients, or from
healthy controls. Therefore, it appears that these com-
plement factors are unlikely to be responsible for the neu-
trophil activation occurring during edematous attacks.
Conclusion
The activity of systemic mechanisms during edematous
episodes suggests their role in edema-formation, even
though the latter is a localized process in C1-INH-HAE.
Our study confirmed that NGC increases during edema-
tous attacks in patients with C1-INH-HAE, and pointed
out that these cells undergo activation. However, ques-
tions arise about the cause behind the increase in the
numbers and the activation of NGs and it needs further
studies to determine whether NG activation is a cause or
a consequence of an edematous attack. The role of these
cells in the spontaneous resolution of edema is similarly
unclear.
As it might prove a new, important aspect of the
pathomechanism of C1-INH-HAE, we plan further re-
search into the circumstances of, as well as the causality
behind neutrophil activation.
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